Please go to the PowerPak homepage
and select a course.
Prevention and Management of Recurrent C. difficile: Expert and Patient Perspectives
This educational activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and supported by an educational grant from Merck & Company.
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Featuring video commentary from two C. difficile patients, Lorraine and Melissa
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CPE activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG
Consultant: Ferring Pharmaceuticals, Merck & Company, Roche Diagnostics
Speakers Bureau: Merck & Company
The following have no relevant financial relationships to report:
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches under investigation for treating and preventing recurrent C. difficile.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.0 hour (0.10 ceu)
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes
November 14, 2019
November 8, 2020
This activity is intended for ID pharmacists and other clinicians who care for patients at risk of C. difficile infection.
How to Earn Credit
To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. There is no fee to participate in the activity. To receive credit, you must provide your date of birth and NABP number. All credit information will be uploaded into CPE monitor within 30 days.
For questions, contact Katlyn Cooper at email@example.com
This activity features two C. difficile patients who discuss their experiences with recurrent C. difficile infection and its impact on their quality of life. Dr. Feuerstadt provides commentary on the patients' risks for initial and recurrent episodes, recent data, and considerations in the selection of antimicrobial therapy. The discussion also provides insights on improving outcomes and the patient experience.
I Patient Case Presentation: Lorraine
II Epidemiology of C. difficile: What Places Patients at-risk?
III Guidelines and Approaches to Reduce Risk in Patients with C. difficile
IV Patient Case Presentation: Melissa
V Prevention of Recurrent C. difficile
VI Gut Microbiome
Upon completion of this program, participants should be better able to:
- Implement tools to identify patients who may be at increased risk for recurrent C. difficile infection
- Outline evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations
- Describe the role of available antimicrobial agents and biologics for treatment and prevention of recurrent C. difficile infection
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing education (CPE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CPE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CPE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.